Morgan Stanley Argenx Se Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Argenx Se stock. As of the latest transaction made, Morgan Stanley holds 429,291 shares of ARGX stock, worth $325 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

429,291

Previous 877,150 51.06%

Holding current value

$325 Million

Previous $519 Million 54.42%

% of portfolio

0.02%

Previous 0.04%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$532.27 - $656.65 $238 Million - $294 Million	-447,859 Reduced 51.06%	429,291 $237 Million
Q1 2025 May 15, 2025	SELL	$571.0 - $671.75 $35.1 Million - $41.2 Million	-61,388 Reduced 6.54%	877,150 $519 Million
Q4 2024 Feb 14, 2025	BUY	$520.52 - $638.33 $4.05 Million - $4.97 Million	7,789 Added 0.84%	938,538 $577 Million
Q3 2024 May 14, 2025	BUY	$434.22 - $551.9 $48.2 Million - $61.2 Million	110,908 Added 13.53%	930,749 $505 Million
Q3 2024 Nov 14, 2024	BUY	$434.22 - $551.9 $48.2 Million - $61.2 Million	110,908 Added 13.53%	930,749 $505 Million
Q2 2024 May 14, 2025	SELL	$356.01 - $451.55 $42.3 Million - $53.6 Million	-118,697 Reduced 12.65%	819,841 $353 Million
Q2 2024 Oct 17, 2024	BUY	$356.01 - $451.55 $44.8 Million - $56.9 Million	125,961 Added 18.15%	819,841 $353 Million
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $44.8 Million - $56.9 Million	125,961 Added 18.15%	819,841 $353 Million
Q1 2024 Oct 17, 2024	SELL	$356.95 - $413.29 $45 Million - $52.1 Million	-125,961 Reduced 15.36%	693,880 $273 Million
Q1 2024 Aug 16, 2024	BUY	$356.95 - $413.29 $14.6 Million - $16.9 Million	40,993 Added 6.28%	693,880 $273 Million
Q1 2024 May 15, 2024	BUY	$356.95 - $413.29 $14.6 Million - $16.9 Million	40,993 Added 6.28%	693,880 $273 Million
Q4 2023 Aug 16, 2024	SELL	$338.91 - $506.01 $56.6 Million - $84.5 Million	-166,954 Reduced 20.36%	652,887 $248 Million
Q4 2023 Feb 13, 2024	BUY	$338.91 - $506.01 $33.2 Million - $49.6 Million	97,977 Added 17.66%	652,887 $248 Million
Q3 2023 Nov 15, 2023	SELL	$369.35 - $548.43 $562,150 - $834,710	-1,522 Reduced 0.27%	554,910 $273 Million
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $3.57 Million - $4.19 Million	9,926 Added 1.82%	556,432 $217 Million
Q1 2023 May 15, 2023	SELL	$334.23 - $403.65 $28 Million - $33.8 Million	-83,824 Reduced 13.3%	546,506 $204 Million
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $152 Million - $178 Million	443,217 Added 236.87%	630,330 $239 Million
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $15 Million - $17.3 Million	43,735 Added 30.5%	187,113 $66.1 Million
Q2 2022 Oct 27, 2022	BUY	$269.58 - $378.88 $24.3 Million - $34.1 Million	90,115 Added 169.19%	143,378 $54.3 Million
Q2 2022 Aug 15, 2022	BUY	$269.58 - $378.88 $24.3 Million - $34.1 Million	90,115 Added 169.19%	143,378 $54.3 Million
Q1 2022 Oct 27, 2022	SELL	$254.45 - $351.06 $22.9 Million - $31.6 Million	-90,115 Reduced 62.85%	53,263 $16.8 Million
Q1 2022 May 13, 2022	BUY	$254.45 - $351.06 $1.63 Million - $2.25 Million	6,415 Added 13.69%	53,263 $16.8 Million
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $7.97 Million - $10.3 Million	29,285 Added 166.74%	46,848 $16.4 Million
Q3 2021 Nov 15, 2021	BUY	$295.0 - $350.58 $5.18 Million - $6.16 Million	17,563 New	17,563 $5.31 Million

Others Institutions Holding ARGX

# of Institutions

491

Shares Held

28.3M

Call Options Held

370K

Put Options Held

211K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $41.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account